Think of Verquvo as a “Niche” Med for Heart Failure
Reps will tout Verquvo (vericiguat) as a new once-daily add-on for worsening heart failure with reduced ejection fraction (HFrEF).
Verquvo is the first “soluble guanylate cyclase stimulator” for HFrEF. It relaxes blood vessels through the nitric oxide pathway.
Most evidence is in patients already on triple therapy...an ACEI, ARB, or Entresto (sacubitril/valsartan), beta-blocker (carvedilol, etc), AND aldosterone antagonist (spironolactone, etc).